NextCell Pharma AB (OSTO:NXTCL) Other Financing: kr33.93 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NXTCL NextCell Pharma AB OSTO:NXTCL
42 GF Score
Price kr1.01
GF Value kr0.90
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is NextCell Pharma AB Other Financing?

NextCell Pharma AB OSTO:NXTCL -0.20% 42 Other Financing is kr33.93 Mil as of Dec. 2025. GuruFocus rates OSTO:NXTCL with a GF Score™ of 42/100 and a GF Value™ of kr0.90 (Modestly Overvalued). The stock has 4 warning signs investors should review.

NextCell Pharma AB's Other Financing for the three months ended in Dec. 2025 was kr0.00 Mil.

NextCell Pharma AB's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was kr33.93 Mil.

NextCell Pharma AB Other Financing Historical Data

* Premium members only.

The historical data trend for NextCell Pharma AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB Other Financing Chart

NextCell Pharma AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.29 0.00 0.00 -6.26 -2.63

NextCell Pharma AB Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 33.93 0.00
OSTO:NXTCL
42GF Score
NextCell Pharma AB OSTO:NXTCL
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NextCell Pharma AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr33.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of kr33.93 Mil mean?
NextCell Pharma AB (OSTO:NXTCL) has a Other Financing of kr33.93 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for NextCell Pharma AB and its competitors.
Is NextCell Pharma AB's Other Financing too high?
NextCell Pharma AB's current Other Financing is kr33.93 Mil. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Other Financing compare to VRTX and REGN?
NextCell Pharma AB's Other Financing of kr33.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for NextCell Pharma AB and its competitors. NextCell Pharma AB's current Other Financing is kr33.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (OSTO:NXTCL) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.90, compared to a current price of kr1.01 — trading 12.2% above its estimated fair value. The current Other Financing is kr33.93 Mil. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For NextCell Pharma AB (OSTO:NXTCL), the current Other Financing is kr33.93 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NextCell Pharma AB (OSTO:NXTCL) Overvalued in 2026?

Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued. The current stock price of kr1.01 is trading 12.2% above its estimated GF Value™ of kr0.90. GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.

Key valuation signals for OSTO:NXTCL:

  • Other Financing: kr33.93 Mil
  • GF Value™: kr0.90 vs. price of kr1.01 (12.2% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the OSTO:NXTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NextCell Pharma AB Business Description

Other Exchanges 65G:Germany
Address Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score

Get the complete analysis for OSTO:NXTCL

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.01
Price
kr0.90
GF Value